
Novel CAR-T approaches targeting both CD19 and BCMA signal a paradigm shift in systemic sclerosis, alongside a growing focus on early diagnosis.

Vishal Kakkar, MD, is a scleroderma specialist at the University of Leeds.

Novel CAR-T approaches targeting both CD19 and BCMA signal a paradigm shift in systemic sclerosis, alongside a growing focus on early diagnosis.